RT Journal Article
SR Electronic
T1 Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.14.20248163
DO 10.1101/2020.12.14.20248163
A1 Gheyath K. Nasrallah
A1 Soha R. Dargham
A1 Farah Shurrab
A1 Duaa W. Al-Sadeq
A1 Hadeel Al-Jighefee
A1 Hiam Chemaitelly
A1 Zaina Al Kanaani
A1 Abdullatif Al Khal
A1 Einas Al Kuwari
A1 Peter Coyle
A1 Andrew Jeremijenko
A1 Anvar Hassan Kaleeckal
A1 Ali Nizar Latif
A1 Riyazuddin Mohammad Shaik
A1 Hanan F. Abdul Rahim
A1 Hadi M. Yassine
A1 Mohamed G. Al Kuwari
A1 Hamda Qotba
A1 Hamad Eid Al Romaihi
A1 Patrick Tang
A1 Roberto Bertollini
A1 Mohamed Al-Thani
A1 Asmaa A. Althani
A1 Laith J. Abu-Raddad
YR 2020
UL http://medrxiv.org/content/early/2020/12/14/2020.12.14.20248163.abstract
AB Background Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 ever (past or current) infection in a population-based sample in a high exposure setting.Methods PCR and serological testing was performed on 394 individuals.Results SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1%-47.8%), 40.6% (95% CI 35.9%-45.5%), and 42.4% (95% CI 37.6%-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2%-95.7%, 89.3%-92.8%, and 93.8%-97.8%, respectively; Cohen kappa statistic ranged from 0.86-0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6%-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9%-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9%-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively.Conclusions All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support provided by Qatar University, Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. Part of this work was made possible by grant No. RRC-2-032 from the Qatar National Research Fund (a member of Qatar Foundation) given to GKN. Finally, we would like to thank the BioMerieux Middle East Regional Office and their distributor in Qatar for providing us with the VidasIII reagent as in-kind support for this project. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research work was approved by the ethics review boards at HMC, QU, and Weill Cornell Medicine-QatarAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available within the manuscript.